Skip to content

Intestinal Organoids

Intestinal Organoids

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05294107
Acronym
BIOÏDES
Enrollment
90
Registered
2022-03-24
Start date
2022-09-06
Completion date
2028-03-07
Last updated
2026-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease, Digestive System Diseases, Inflammatory Bowel Disease, Ulcerative Colitis Type

Keywords

biobank, organoids, digestive disease, inflammatory bowel disease

Brief summary

Over the last decade, the use of mini-organ or organoids has been increasingly developed in fundamental research. Indeed, digestive organoids represent an essential advance compared to classical culture systems (epithelial cell lines, immortalized cells) since they preserve in culture the functional complexity present in vivo (architecture, different cell types). They also have the advantage of being able to be propagated indefinitely (unlike explants), minimizing the use of animal models and reducing the amount of tissue required. Finally, their growth and development depends on the origin of the sample (the organoid will develop differently if the cell source comes from a patient suffering from an inflammatory bowel disease, for example), thus generating models of human pathologies to better determine their physiopathology. The use of organoids in biomedical research has proven to be an indispensable tool for the understanding of cellular and molecular mechanisms involved in epithelial renewal and the screening of molecules and ingredients for applications in the health and agri-food sectors.

Detailed description

The project aims to generate a biocollection of 3D intestinal models from digestive biopsies with associated health data and to characterize them before using them for the screening of potential therapeutic molecules.

Interventions

After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up: * 6 biopsies are taken on average in clinical routine * 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB). Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing.

Sponsors

Rennes University Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

Prospective, monocentric cohort aiming at generating 3D organoids from human digestive samples

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Subjects aged 18 to 75 years * Subject undergoing endoscopy as part of the standard of care with the need to take digestive biopsy samples * Subject having signed a free and informed consent in writing

Exclusion criteria

* Subjects under legal protection (safeguard of justice, curatorship or guardianship) or deprived of liberty. * Anticoagulant treatment and anti-platelet treatment (except for aspirin 75 mg)

Design outcomes

Primary

MeasureTime frameDescription
Number of isolated intestinal crypts per biopsiesDay 0Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing.

Secondary

MeasureTime frame
Number of differentiated organoidsDay 0
Fold change of MUC2 expressionDay 0
Fold change of LGR5 expressionDay 0
KI67 expressionDay 0

Countries

France

Contacts

CONTACTGuillaume BOUGUEN, Professor
guillaume.bouguen@chu-rennes.fr2 99 28 99 72
PRINCIPAL_INVESTIGATORGuillaume BOUGUEN, Professor

Rennes University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 18, 2026